Pt. Otsuka Indonesia
PT Otsuka Indonesia is a pharmaceutical manufacturer established in 1974 as a joint venture with Otsuka Pharmaceutical Co., Ltd., Japan, producing infusion solutions, ethical drugs, clinical nutrition, and medical equipment for hospitals, pharmacies, and export markets across 11 countries.
- Company typePrivate
- Founded1974
- HeadquartersJakarta, Indonesia
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Pt. Otsuka Indonesia does
PT Otsuka Indonesia is a privately held pharmaceutical manufacturer established in 1974 as a joint venture with Otsuka Pharmaceutical Co., Ltd., Japan. The company manufactures and markets a diversified portfolio of pharmaceutical products and medical devices from a 48,397m² facility in Lawang, East Java, with corporate headquarters in South Jakarta. Core product lines include intravenous (infusion/injection) fluids — described as the company's market-leading category in Indonesia — alongside ethical drugs, clinical nutrition products for special medical purposes, therapeutics drug medical food, and medical equipment. The portfolio has been progressively extended, with PROTEN GOLD (a nutritional supplement for multi-drug-resistant tuberculosis patients) launched in 2016 and PROTERAL Junior (a sucrose-free child growth milk for ages 1–3) launched in November 2025. Products are manufactured under GMP, GMPMD, ISO 9001, ISO 22000, ISO 14001, ISO 50001, Halal, and AEO certifications.
The company operates a prescription-based, sales-led go-to-market model. Direct sales are conducted by medical representatives and regional managers targeting public and private hospitals, clinics, and pharmacies across Indonesia. Distribution is supplemented by pharmacy wholesale channels and a dedicated Otsuka Group distribution arm (PT Otsuka Distribution Indonesia), while PT Merapi Utama Pharma handles related pharmaceutical trading. Beyond the domestic market, PT Otsuka Indonesia exports to 11 countries spanning Southeast Asia, South Asia, and Africa (Hong Kong, Singapore, Malaysia, Myanmar, Vietnam, Philippines, Mongolia, Sri Lanka, Thailand, India, and Egypt). Revenue is generated through one-time product sales to institutional and pharmacy buyers, with no public pricing disclosed. Customer engagement is reinforced through a healthcare-professional portal (otsukailmu.id), health-information content marketing, CSR programs (including long-standing MDR-TB patient feeding initiatives with Indonesia IMTC), and participation in health-awareness events such as World TB Day.
PT Otsuka Indonesia sits within the broader Otsuka Group ecosystem alongside PT Amerta Indah Otsuka (beverages, including Fibe-mini), PT Lautan Otsuka Chemical, PT Widatra Bhakti, PT Merapi Utama Pharma, and the Japan-based parent Otsuka Pharmaceutical Co., Ltd. The company received the highest-tier BPOM Environmental Sustainability Award (Titanium) in 2023 and the EWTB Exemplar Award for workplace tuberculosis efforts in 2024. The organization marked its 50th anniversary in Indonesia in 2025, coinciding with the launch of the "Mental Ease at Workplaces" program.
Pt. Otsuka Indonesia firmographics
Firmographics- Name
- Pt. Otsuka Indonesia
- Legal name
- PT Otsuka Indonesia
- Website
- https://otsuka.co.id
- Company type
- Private
- Founded year
- 1974
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- PT Otsuka Indonesia is a pharmaceutical manufacturer established in 1974 as a joint venture with Otsuka Pharmaceutical Co., Ltd., Japan, producing infusion solutions, ethical drugs, clinical nutrition, and medical equipment for hospitals, pharmacies, and export markets across 11 countries.
- Ownership category
- akta.pro rank
Pt. Otsuka Indonesia industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Generic Hospital & Institutional Products (HLAIABAL)
- akta.pro secondary industry
- Generic Tender & Government Supply Markets (HLAIABAM)
Keywords
Where Pt. Otsuka Indonesia is headquartered
LocationHeadquarters
- HQ city
- Jakarta
- HQ country
- Indonesia
- HQ region
- Asia
Offices2 records
Markets served
Pt. Otsuka Indonesia business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Pharmaceutical Products Sales: Sale of infusion solutions, ethical drugs, clinical nutrition products, therapeutics drug medical food, and medical equipment to hospitals, pharmacies, and healthcare facilities across Indonesia and export markets.
- Export Revenue: Export of pharmaceutical and nutritional products to 11 countries including Hong Kong, Singapore, Malaysia, Myanmar, Vietnam, Philippines, Mongolia, Sri Lanka, Thailand, India, and Egypt.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Pt. Otsuka Indonesia product offering
Product offeringCore offering
PT Otsuka Indonesia manufactures and sells pharmaceutical and medical products from its 48,397m² facility in Lawang, East Java. Its portfolio includes infusion/injection fluids (the market-leading category in Indonesia), ethical (prescription) drugs, clinical nutrition products for special medical purposes, therapeutics drug medical food, and medical equipment, with exports to 11 countries. The company also produces specialized items such as PROTEN GOLD nutritional supplement for MDR-TB patients and PROTERAL Junior child growth milk.
Product overview
PT Otsuka Indonesia is a pharmaceutical company established in 1974 as a joint venture with Otsuka Pharmaceutical Co., Ltd., Japan. The company operates from a 48,397m² facility in Lawang, East Java, and offers a diversified portfolio of pharmaceutical and health products. Core offerings include Infusion/Injection Fluids (the market-leading product line), Ethical Drugs, Clinical Nutrition, Therapeutics Drug Medical Food, and Medical Equipment. Recent additions include PROTERAL Junior (child growth milk launched November 2025) and PROTEN GOLD (nutritional supplement for MDR-TB patients). The company exports products to Hong Kong, Singapore, Malaysia, Myanmar, Vietnam, Philippines, Mongolia, Sri Lanka, Thailand, India, and Egypt.
Differentiator
Problem solved
Functional benefit
Products and services
- Infusion/Injection Fluids
Quantifiable outcome
- Leader in Infusion Solutions business in Indonesia
- +1 more outcomes
Companies that use Pt. Otsuka Indonesia
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Pt. Otsuka Indonesia technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Pt. Otsuka Indonesia partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core, flagship and minor.
- Yayasan Indonesia IMTCcoreFoundation partner for MDR-TB care initiatives. Participated together with PT Otsuka Indonesia at World TB Day 2018 commemoration at Monas field, sharing information about TB activities and spreading education about TB in communities.
- Indonesia IMTC (Initiative on MDR TB Care)coreCollaboration with Indonesia IMTC to increase nutritional status of MDR TB patients in Jakarta and surrounding areas. Since 2013, PT Otsuka Indonesia has provided supplementary feeding for TB patients in various locations including Depok, Bandung, Jakarta, Surabaya, and Malang through this partnership.
- Otsuka Pharmaceutical Co., Ltd., JapanflagshipParent company and joint venture partner established in 1974. Otsuka Pharmaceutical Co., Ltd. is the founding partner of PT Otsuka Indonesia, providing pharmaceutical expertise, technology transfer, and global brand support. The partnership enables access to Otsuka Group's global research and development capabilities.
- PT Amerta Indah OtsukacoreRelated company within Otsuka Group in Indonesia, operating in beverage and consumer product segment. Launched Fibe-mini fiber beverage product in 2021.
- PT Merapi Utama PharmaminorOtsuka Group company in Indonesia engaged in pharmaceutical distribution and trading.
- PT Otsuka Distribution IndonesiacoreOtsuka Group distribution company in Indonesia facilitating product distribution across the archipelago.
- PT Widatra BhaktiminorOtsuka Group company in Indonesia operating in food and beverage sector.
- PT Lautan Otsuka ChemicalminorOtsuka Group chemical company in Indonesia.
- Otsuka Pharmaceutical Factory, Inc. (OPF)coreJapan-based related company providing infusion solution technology and training programs. OPF conducted training for PT Otsuka Indonesia sales and marketing teams on incompatibility and risk management during infusion delivery.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Pt. Otsuka Indonesia competitors and assessment
Company assessmentDirect peers
- PT Dexa Medica: Indonesian pharmaceutical manufacturer focused on prescription medicines, herbal products, and medical devices. Comparable as a domestic competitor in ethical drugs and hospital-supply categories.
- PT B. Braun Medical Indonesia: Indonesian subsidiary of B. Braun, producing IV infusion solutions and medical devices for hospitals. Closely comparable as a specialist manufacturer of infusion solutions and hospital medical equipment.
- PT Sanbe Farma: Indonesian pharmaceutical manufacturer producing generic and branded prescription drugs, infusion solutions, and medical devices. Direct competitor in infusion solutions and hospital ethical drugs.
- PT Kalbe Farma: Indonesia's largest pharmaceutical manufacturer, producing prescription drugs, OTC products, and nutritional supplements. Directly comparable as a domestic Indonesian pharma manufacturer serving hospitals, pharmacies, and consumer health channels.
- PT Taisho Pharmaceutical Indonesia: Indonesian subsidiary of Japanese pharma company Taisho Pharmaceutical, producing OTC and ethical drugs. Comparable as a Japanese-affiliated pharma manufacturer operating in Indonesia with similar regional export orientation.
Broad incumbents
- PT Abbott Indonesia: Indonesian subsidiary of Abbott, producing nutritional products and pharmaceuticals. Comparable in the clinical nutrition and hospital product segments where PT Otsuka Indonesia competes.
- PT Pfizer Indonesia: Indonesian subsidiary of global pharma major Pfizer, manufacturing and marketing prescription pharmaceuticals. Comparable as a multinational pharma subsidiary serving the Indonesian hospital and pharmacy channel.
- PT Merck Sharp Dohme Indonesia: Indonesian arm of MSD (Merck), selling prescription pharmaceuticals and vaccines to hospitals and clinics. Comparable as a multinational pharma subsidiary serving similar institutional customers in Indonesia.
- PT Sanofi Indonesia: Indonesian subsidiary of Sanofi, manufacturing and selling prescription drugs, vaccines, and consumer health products. Comparable as a foreign-investment pharma manufacturer in Indonesia serving hospitals and pharmacies.
Regional players
- PT Nutricia Indonesia (Danone): Indonesian arm of Danone's Nutricia, producing clinical and pediatric nutrition products. Comparable in the medical/clinical nutrition category where PROTERAL Junior competes.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Pt. Otsuka Indonesia social profiles
Digital presencePt. Otsuka Indonesia compliance and trust
Trust signalCompliance9 records
Pt. Otsuka Indonesia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pt. Otsuka Indonesia leadership team
Management profileNumber of profiles
Profiles3 records
Pt. Otsuka Indonesia funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pt. Otsuka Indonesia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pt. Otsuka Indonesia
What does Pt. Otsuka Indonesia do?
PT Otsuka Indonesia manufactures and sells pharmaceutical and medical products from its 48,397m² facility in Lawang, East Java. Its portfolio includes infusion/injection fluids (the market-leading category in Indonesia), ethical (prescription) drugs, clinical nutrition products for special medical purposes, therapeutics drug medical food, and medical equipment, with exports to 11 countries. The company also produces specialized items such as PROTEN GOLD nutritional supplement for MDR-TB patients and PROTERAL Junior child growth milk.
Is Pt. Otsuka Indonesia a public or private company?
Pt. Otsuka Indonesia is a private company. It is classified as corporate owned and is currently operating.
When was Pt. Otsuka Indonesia founded?
Pt. Otsuka Indonesia was founded in 1974. It employs 501 to 1,000 people.
Where is Pt. Otsuka Indonesia based?
Pt. Otsuka Indonesia is headquartered in Jakarta, Indonesia, in the Asia region.
How does Pt. Otsuka Indonesia make money?
Two revenue lines are on record. Pharmaceutical Products Sales are the primary driver. The others are export Revenue.
Who are Pt. Otsuka Indonesia's main competitors?
Direct peers on record are PT Dexa Medica, PT B. Braun Medical Indonesia, PT Sanbe Farma, PT Kalbe Farma and PT Taisho Pharmaceutical Indonesia. Broad incumbents are PT Abbott Indonesia, PT Pfizer Indonesia, PT Merck Sharp Dohme Indonesia and PT Sanofi Indonesia. PT Nutricia Indonesia (Danone) is listed as a regional player.
Does Pt. Otsuka Indonesia have an API?
No public API is recorded for Pt. Otsuka Indonesia.
What industry is Pt. Otsuka Indonesia in?
Pt. Otsuka Indonesia's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIABAM, Generic Tender & Government Supply Markets. Its NAICS code is 325412 and its SIC code is 2834.